Resolve Therapeutics Obtains $5,800,000 Series B Round

  • Feed Type
  • Date
    11/1/2012
  • Company Name
    Resolve Therapeutics
  • Mailing Address
    5400 Carillon Point Kirkland, WA 98033
  • Company Description
    Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-125, its novel targeted biologic therapy.
  • Website
    http://www.resolvebio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,800,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    These funds give Resolve the necessary resources to advance our investigational lupus compound RSLV-132 into clinical trials, which we expect to start in mid-2013.
  • M&A Terms
  • Venture Investor
    New Science Ventures
  • Venture Investor
    WRF Capital
  • Venture Investor
    Easton Capital

By posting a comment, you agree to our terms and conditions.